Xbrane And Stada’s Ranibizumab Snapped Up In North America
Bausch + Lomb Licenses Biosimilar Lucentis Rival For US And Canada
Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.
You may also be interested in...
With plans to obtain EU and US marketing authorizations for its Xlucane ranibizumab biosimilar, Xbrane has renegotiated a pre-existing intellectual property licensing agreement with Vaxiion Therapeutics, including the payment of royalties through February 2024.
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.